CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8,575 enrolled
Drug / intervention
Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00638794
NCT00638794N/ACompleted
CompareCT.gov

Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents

Cardiovascular Research Foundation, New York·observational·Posted Mar 19, 2008·Updated Jan 23, 2013

In Brief

An observational study evaluating Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™) for Coronary Artery Disease. Completed, enrolled 8,575 participants across 8 sites.

Detailed Summary

Prospective, multicenter, registry of at least 11,000 (and up to 15,000) consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
CollaboratorsDickson Advanced Analytics Group

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 19, 2008
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.3 years ago

Interventions

Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)device

PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System